RecruitingNot applicableNCT07184853

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
First Affiliated Hospital of Zhejiang University
Intervention
Ruxolitinib (JAKAVI®)(drug)
Enrollment
122 enrolled
Eligibility
12-70 years · All sexes
Timeline
20252028

Study locations (1)

Collaborators

The First Affiliated Hospital of Zhengzhou University · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · The Children's Hospital of Zhejiang University School of Medicine · Ruijin Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07184853 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials